Australia
Brazil
Canada
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom
Biotech Hangout
Also in Life Sciences
Science
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
by BZ Group
If you like The Pharma Closeout | Daily…, try…
Cancer Connections
Also in Life Sciences
The Chain: Protein Engineering Podcast
Also in Life Sciences
Talking Transfusion: The Transfusion Evidence Round-Up Podcast
Also in Life Sciences
Clinical Pharmacology Podcast with Nathan Teuscher
Also in Life Sciences
Inside Neuroscience
Also in Life Sciences
Latest episodes
-
Daily Roundup | BioNTech/DualityBio Breast ADC Gain Called Modest & Merck's sac-TMT Survival Edge Under FDA Review
October 27, 2026 · 9 minOctober 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27. BioNTech and DualityBio's breast cancer ADC beat chemo in Phase 3, yet the companies call the gain…
-
Week in Review | Amgen's Survival Gain, Roche's KRAS Challenge & Gilead's IBD Deal
October 26, 2026 · 30 minSunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from 12.7 in extensive-stage small-cell lung cancer maintenance, while…
-
Daily Roundup | Remibrutinib Cuts MS Relapses & Iza-bren Improves Breast Cancer PFS
October 25, 2026 · 14 minDelayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23. Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's…
-
UEG Week 2026 Debrief: Takeda's Treat-to-Target Test & Duvakitug's 44-Week TL1A Read
October 24, 2026 · 19 minThe Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. Takeda's VERDICT, the first randomized treat-to-target strategy trial…
-
Daily Roundup | Merck-Moderna mRNA Cuts Melanoma Recurrence or Death & AbbVie HS Drug Hits Phase 3 Goal
October 23, 2026 · 11 minOctober 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff. Merck and Moderna's investigational intismeran autogene, added to Keytruda (pembrolizumab) after surgery for high-risk cutaneous melanoma…
Show 7 more episodesShow fewer episodes
-
Daily Roundup | Brepocitinib Holds Uveitis Control Off Steroids; Oral Olorofim Shows Far Fewer Kidney Events
October 22, 2026 · 13 minOctober 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21. Roivant's Priovant reports two positive Phase 3 trials of oral brepocitinib in non-infectious uveitis, run through a mandatory steroid taper…
-
Daily Roundup | GSK's Hibsago Offers a Path Off Hepatitis B Treatment & Tezspire Details EoE Data
October 21, 2026 · 14 minFDA approved GSK's Hibsago (bepirovirsen) for selected adults with chronic hepatitis B without cirrhosis, opening a possible path off long-term treatment after a staged treatment and testing process. We examine who qualifies, the B-Well…
-
Daily Roundup | GSK's Jemperli Wins Accelerated Approval & Disc's Bitopertin Meets Phase 3 Endpoints
October 20, 2026 · 12 minFDA granted accelerated approval to GSK's Jemperli (dostarlimab) for biomarker-defined locally advanced rectal cancer, with continued surveillance required for responders. Disc Medicine's bitopertin met both Phase 3 APOLLO co-primary…
-
AAO 2026 Debrief: Retina's Durability Race & A Stargardt Pill Heads to an FDA Decision
October 19, 2026 · 13 minThe Pharma Closeout's AAO 2026 Debrief covers the readouts from the American Academy of Ophthalmology meeting in New Orleans that matter for drug, device and payer strategy. Kodiak's DAYBREAK and Ocular Therapeutix's SOL-1 show retina's…
-
Week in Review | Revita Slows Regain After Tirzepatide at Six Months; Liquidia Settles With United Therapeutics
October 19, 2026 · 46 minFractyl Health reports that its investigational Revita met the six-month co-primary endpoint of the double-blind, sham-controlled REMAIN-1 pivotal study in adults who lost weight on tirzepatide and then stopped it; the twelve-month…
-
Daily Roundup | Enspryng Approved for Thyroid Eye Disease as Home Injection & Omeros Refused Again by EU Panel
October 17, 2026 · 12 minFriday, October 16 edition. Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and…
-
Daily Roundup | Anktiva Expands Bladder Cancer Label & Vanda's Anxiety Trial Misses
October 16, 2026 · 14 minFDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a…
About the show
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.